Clinical introduction of this strategy with the humanized anti-ErbB2 antibody trastuzumab (Herceptin®) has been successful, but chronic treatment has been disturbed by unforeseen problems, namely, (a) the development of tumor drug resistance and (b) the induction of cardiac dysfunction and heart failure [23]. The gene discussed is ERBB2; the disease is heart failure.